Continuous, real-time diagnosis using blood pressure and heart rate (Volume) ejection fractions, defined as the ratio of difference of ventricular volumes prior to and after ejection of blood measures to the ventricular volume prior to ejection, measure the efficiency with which the heart pumps. The American Heart Association recognizes it as a quality indicator in the management of heart failure patients [1]. Universal use of (volume) ejection fraction as a diagnostic tool is limited by the lack of continuous measurements. As the heart must satisfy instant demand, ejection fraction should be measured continuously, in real time, and preferably noninvasively. These conditions can be met, if (pressure) ejection fractions are derived from blood pressure data.The numerator of the pressure ejection fraction is represented by the pulse pressure. Clinical experience shows that pulse pressure provides information concerning blood flow. In case of an equal arterial mean pressure of 65 mmHg, the peripheral tissue of the extremities will be cold in low pulse pressure of 75/60 mmHg compared with warm skin in higher pulse pressure of 105/50 mmHg, for example.The pulse wave analysis technology, applied in PiCCO™ and Vigileo-™/ FloTrec™, draws flow information from arterial blood pressure. Thus, Ohm's law predicts that the mean arterial pressure and cardiac output are mathematically related; on the other hand, the pulse pressure reflects the pulsatile component of blood pressure [2]. The Vigileo™/FloTrec™ technology is based on the direct proportionality of pulse pressure and stroke volume [3,4,5]. As a consequence, the pressure ejection fraction can be viewed as a parameter containing pressure and flow.Another important parameter is the pressure-heart rate product [6], which is given by the product of systolic pressure and heart rate. The product has been found to be indicative of myocardial oxygen consumption. It can also be measured continuously and non-invasively; thus, it reflects instant status.The objective of this investigation is to determine whether ejection fractions derived as the ratio of the difference of arterial systolic pressure and arterial diastolic pressure to arterial systolic pressure, pressure-heart rate product, and/or combinations thereof yield useful diagnostic results, which may be obtained noninvasively, continuously, and in real time. A further objective is to demonstrate the possible use of ejection fractions and the pressure-heart rate product to monitor patient safety.
Materials and methods
(Volume) ejection fraction, EF(V) is defined aswhere EDV is the end-diastolic volume and ESV is the end-systolic volume. In analogy to the definition of EF(V), a (pressure) ejection fraction, EF(P), can be defined as